Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) CFO Gina Consylman sold 4,055 shares of the stock in a transaction on Friday, May 10th. The shares were sold at an average price of $10.53, for a total value of $42,699.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Gina Consylman also recently made the following trade(s):
- On Thursday, February 21st, Gina Consylman sold 5,677 shares of Ironwood Pharmaceuticals stock. The shares were sold at an average price of $14.31, for a total value of $81,237.87.
Shares of NASDAQ:IRWD traded up $0.24 during midday trading on Thursday, hitting $10.04. The company’s stock had a trading volume of 14,388 shares, compared to its average volume of 1,498,202. The company has a market cap of $1.52 billion, a P/E ratio of -10.43 and a beta of 1.89. Ironwood Pharmaceuticals, Inc. has a fifty-two week low of $9.07 and a fifty-two week high of $21.20.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its earnings results on Thursday, May 2nd. The biotechnology company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.10). The company had revenue of $68.73 million during the quarter, compared to analyst estimates of $81.93 million. During the same quarter in the previous year, the business posted ($0.25) earnings per share. The firm’s quarterly revenue was down .6% compared to the same quarter last year. Research analysts predict that Ironwood Pharmaceuticals, Inc. will post -0.12 EPS for the current fiscal year.
Hedge funds have recently added to or reduced their stakes in the stock. CWM LLC acquired a new stake in Ironwood Pharmaceuticals during the fourth quarter worth about $31,000. CWM Advisors LLC acquired a new stake in Ironwood Pharmaceuticals during the first quarter worth about $154,000. First Manhattan Co. acquired a new stake in Ironwood Pharmaceuticals during the fourth quarter worth about $133,000. Gotham Asset Management LLC acquired a new stake in Ironwood Pharmaceuticals during the fourth quarter worth about $135,000. Finally, NumerixS Investment Technologies Inc acquired a new stake in Ironwood Pharmaceuticals during the first quarter worth about $190,000. 97.04% of the stock is currently owned by institutional investors and hedge funds.
A number of analysts have recently issued reports on IRWD shares. BidaskClub upgraded Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, January 17th. HC Wainwright upgraded Ironwood Pharmaceuticals from a “sell” rating to a “neutral” rating and increased their target price for the company from $11.50 to $14.00 in a report on Monday, February 25th. Morgan Stanley set a $13.00 target price on Ironwood Pharmaceuticals and gave the company a “hold” rating in a report on Friday, May 3rd. Wood & Company reiterated a “buy” rating on shares of Ironwood Pharmaceuticals in a report on Thursday, January 31st. Finally, Zacks Investment Research upgraded Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, January 28th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and six have given a buy rating to the stock. Ironwood Pharmaceuticals has a consensus rating of “Hold” and an average target price of $15.15.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from IBS with diarrhea; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD.
Recommended Story: Why is the Consumer Price Index (CPI) important?
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.